HomePulse Biosciences Inc.

Pulse Biosciences Inc.

Update on FDA 510(k) Submission for the CellFX System in Dermatology: Reported by Pulse Biosciences

We remain highly confident in the CellFX System and its safety and efficacy profile in aesthetic dermatology. We look forward to continuing to work with FDA to obtain a clearance for the CellFX system in dermatology.” said Darrin Uecker, President and CEO of Pulse Biosciences.

Nano-Pulse Stimulation Technology Study Shows Positive Results

4/13/18: Results will be featured at the 2018 American Society for Laser Medicine and Surgery Annual Conference in DallasPulse Biosciences, Inc. (Nasdaq:PLSE) announced clinical efficacy results of its first multi-center study of Nano-Pulse Stimulation (NPS) technology for the treatment of seborrheic keratosis lesions (SKs) in humans. The findings will be featured at the 2018 American Society for Laser Medicine and Surgery (ASLMS) Annual Conference to be held in Dallas on April 11-15, 2018. The company also will present data from the first-in-human clinical study of NPS dose-response effects. These definitive studies establish the foundation for future therapeutic applications of NPS across a range of benign and cancerous skin growths.